Main Article Content
The study has evaluated the effectiveness of antiplatelet therapy of patients with chronic kidney disease. The patients were divided into two groups when treating the disease, the first group was given allthrombosepin as antiplatelet therapy, and the second group was given dipyridamole. The research work was monitored for ten days, during which the amount of urea in the blood was 9.6% compared to healthy people and a decrease in the amount of creatinine to 7.52%. Aggregation of thrombocytes was observed in the first group by 10.23%, and 9.6% was in the second group. As can be seen from the results obtained, it has been proved that dipyridamole did not lag in effectiveness, which was taken from the factory as an antiplatelet therapy and was used with the locally developed allthrombosepin, as traditional treatment, while treating chronic kidney disease (CKD).
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.